Post by Organon

For US audiences only. We’re excited to present new analysis of pooled Phase 3 data at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting that evaluates efficacy and safety for one of our dermatology treatments for atopic dermatitis across age groups in adults and pediatric patients 2 years of age and older. Read more: https://bit.ly/4w0eOS3   #OrganonDermatology #SPD2026